Literature DB >> 28138204

A Case of Olanzapine-Induced Fever.

Cho-Hsiang Yang1, Ying-Yeh Chen1.   

Abstract

Olanzapine, a frequently used second-generation antipsychotic, has rarely been implicated as a cause of drug-induced fever in the absence of neuroleptic malignant syndrome. We describe a patient who developed isolated fever following olanzapine monotherapy, which subsided after discontinuation of olanzapine. Blockade of dopaminergic receptors and elevated cytokines concentration are possible mechanisms of fever development during treatment with olanzapine. This case calls for attention to olanzapine-induced fever in clinical practice.

Entities:  

Keywords:  cytokine; dopamine antagonism; fever; olanzapine

Mesh:

Substances:

Year:  2017        PMID: 28138204      PMCID: PMC5274531     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  4 in total

1.  A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol.

Authors:  Chantal P Bleeker-Rovers; Fidel J Vos; Elisabeth M H A de Kleijn; Aart H Mudde; Ton S M Dofferhoff; Clemens Richter; Tineke J Smilde; Paul F M Krabbe; Wim J G Oyen; Jos W M van der Meer
Journal:  Medicine (Baltimore)       Date:  2007-01       Impact factor: 1.889

Review 2.  Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine.

Authors:  Anna Szota; Ewa Ogłodek; Aleksander Araszkiewicz
Journal:  Pharmacol Rep       Date:  2013       Impact factor: 3.024

3.  Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever.

Authors:  Michael Kluge; Andreas Schuld; Alexander Schacht; Hubertus Himmerich; Mira A Dalal; Peter M Wehmeier; Dunja Hinze-Selch; Thomas Kraus; Ralf W Dittmann; Thomas Pollmächer
Journal:  Psychoneuroendocrinology       Date:  2008-10-04       Impact factor: 4.905

Review 4.  Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective.

Authors:  Lurdes Tse; Alasdair M Barr; Vanessa Scarapicchia; Fidel Vila-Rodriguez
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.